Sernova (TSE:SVA – Free Report) had its price target trimmed by Leede Financial from C$3.00 to C$1.50 in a research report sent to investors on Friday, BayStreet.CA reports. The firm currently has a speculative buy rating on the stock. Leede Financial also issued estimates for Sernova’s FY2027 earnings at ($0.02) EPS.
Sernova Price Performance
TSE:SVA opened at C$0.26 on Friday. The firm has a market cap of C$82.72 million, a price-to-earnings ratio of -1.96 and a beta of 1.38. The company has a current ratio of 0.62, a quick ratio of 18.11 and a debt-to-equity ratio of 16.55. The company’s 50-day moving average is C$0.27 and its two-hundred day moving average is C$0.37. Sernova has a 12-month low of C$0.20 and a 12-month high of C$0.83.
Sernova (TSE:SVA – Get Free Report) last released its earnings results on Friday, June 14th. The company reported C($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of C($0.03). Research analysts expect that Sernova will post -0.08 EPS for the current year.
Insider Transactions at Sernova
About Sernova
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.
Featured Stories
- Five stocks we like better than Sernova
- What is a buyback in stocks? A comprehensive guide for investors
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- How to buy stock: A step-by-step guide for beginnersÂ
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- What Are Dividends? Buy the Best Dividend Stocks
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Sernova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sernova and related companies with MarketBeat.com's FREE daily email newsletter.